Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1134) 1134
humans (870) 870
male (572) 572
animals (489) 489
female (446) 446
dipeptides - therapeutic use (347) 347
dipeptides - adverse effects (334) 334
dipeptides - pharmacology (324) 324
middle aged (296) 296
adult (272) 272
dipeptides - administration & dosage (216) 216
pharmacology & pharmacy (216) 216
adamantane - analogs & derivatives (209) 209
aged (209) 209
rats (202) 202
diabetes mellitus, type 2 - drug therapy (167) 167
mice (157) 157
abridged index medicus (145) 145
double-blind method (134) 134
treatment outcome (128) 128
adamantane - therapeutic use (123) 123
adamantane - adverse effects (121) 121
analysis (105) 105
endocrinology & metabolism (105) 105
saxagliptin (103) 103
dipeptidyl-peptidase iv inhibitors - therapeutic use (101) 101
dose-response relationship, drug (99) 99
type 2 diabetes (98) 98
time factors (91) 91
dipeptidyl-peptidase iv inhibitors - adverse effects (90) 90
peptides (89) 89
hypoglycemic agents - therapeutic use (87) 87
enalapril (84) 84
dipeptides - metabolism (81) 81
biochemistry & molecular biology (80) 80
drug therapy, combination (79) 79
care and treatment (77) 77
diabetes (76) 76
hypoglycemic agents - adverse effects (74) 74
research (74) 74
aspartame - adverse effects (72) 72
dipeptides - pharmacokinetics (71) 71
dipeptides (69) 69
hypertension - drug therapy (69) 69
disease models, animal (68) 68
risk factors (68) 68
dipeptides - chemistry (67) 67
metformin (67) 67
double-blind (66) 66
drug therapy (66) 66
oncology (65) 65
health aspects (64) 64
neurosciences (64) 64
proteins (61) 61
administration, oral (60) 60
expression (60) 60
glutamine (59) 59
therapy (59) 59
adolescent (58) 58
medicine, general & internal (58) 58
nutrition & dietetics (58) 58
adamantane - administration & dosage (57) 57
immunology (57) 57
medicine, research & experimental (57) 57
muramyl dipeptide (56) 56
cancer (55) 55
clinical trials (53) 53
diabetes mellitus, type 2 - blood (52) 52
safety (50) 50
cell biology (49) 49
clinical trials as topic (49) 49
lisinopril (49) 49
medicine & public health (49) 49
metabolism (49) 49
studies (49) 49
article (48) 48
dipeptidyl peptidase-4 inhibitor (48) 48
improves glycemic control (48) 48
rats, sprague-dawley (48) 48
blood pressure - drug effects (47) 47
hypoglycemic agents - administration & dosage (47) 47
internal medicine (46) 46
oxidative stress (46) 46
rats, wistar (46) 46
toxicology (46) 46
dipeptides - blood (45) 45
efficacy (45) 45
blood glucose - metabolism (44) 44
dosage and administration (44) 44
amino acids (43) 43
cardiac & cardiovascular systems (43) 43
medicine (43) 43
mice, inbred c57bl (43) 43
angiotensin-converting enzyme inhibitors (42) 42
glucose (42) 42
in-vitro (42) 42
young adult (42) 42
aged, 80 and over (41) 41
chemistry, medicinal (41) 41
dipeptidyl-peptidase iv inhibitors - administration & dosage (41) 41
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1216) 1216
Russian (18) 18
German (12) 12
Chinese (6) 6
French (6) 6
Danish (3) 3
Italian (2) 2
Norwegian (2) 2
Spanish (2) 2
Swedish (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: A retrospective cohort study
by Toh, Sengwee and Hampp, Christian and Reichman, Marsha E and Graham, David J and Balakrishnan, Suchitra and Pucino, Frank and Hamilton, Jack and Lendle, Samuel and Iyer, Aarthi and Rucker, Malcolm and Pimentel, Madelyn and Nathwani, Neesha and Griffin, Marie R and Brown, Nancy J and Fireman, Bruce H
Annals of Internal Medicine, ISSN 0003-4819, 06/2016, Volume 164, Issue 11, pp. 705 - 714
Recent postmarketing trials produced conflicting results about the risk for hospitalized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4)... 
Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Humans | Middle Aged | Risk Factors | Male | Hospitalization | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Female | Retrospective Studies | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Heart Failure - chemically induced | Adamantane - adverse effects | Adamantane - analogs & derivatives | Sitagliptin Phosphate - adverse effects | Heart failure | Complications and side effects | Hospital care | Sitagliptin | Forecasts and trends | Risk factors | Saxagliptin | Prescription drugs | Cardiology | Risk assessment | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
by Scirica, Benjamin M and Bhatt, Deepak L and Braunwald, Eugene and Steg, P. Gabriel and Davidson, Jaime and Hirshberg, Boaz and Ohman, Peter and Frederich, Robert and Wiviott, Stephen D and Hoffman, Elaine B and Cavender, Matthew A and Udell, Jacob A and Desai, Nihar R and Mosenzon, Ofri and McGuire, Darren K and Ray, Kausik K and Leiter, Lawrence A and Raz, Itamar and Savor-Timi Steering Comm Investig and SAVOR-TIMI 53 Steering Committee and Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
by Rosenstock, J and Hansen, L and Zee, P and Li, Y and Cook, W and Hirshberg, B and Iqbal, N
DIABETES CARE, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 376 - 383
OBJECTIVE This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | EFFICACY | SGLT2 INHIBITOR | SAFETY | CLINICAL-TRIALS | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | PLACEBO-CONTROLLED TRIAL | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Dosage and administration | Glycemic index | Metformin | Saxagliptin | Drug therapy | Diabetes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
by Hofman, Michael S and Violet, John and Hicks, Rodney J and Ferdinandus, Justin and Thang, Sue Ping and Akhurst, Tim and Iravani, Amir and Kong, Grace and Ravi Kumar, Aravind and Murphy, Declan G and Eu, Peter and Jackson, Price and Scalzo, Mark and Williams, Scott G and Sandhu, Shahneen
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 825 - 833
Progressive metastatic castration-resistant prostate cancer is a highly lethal disorder and new effective therapeutic agents that improve patient outcomes are... 
SURVIVAL | PSMA | PREDNISONE | MEMBRANE ANTIGEN-EXPRESSION | RESPONSE CRITERIA | ONCOLOGY | RADIOLIGAND THERAPY | CLINICAL-TRIALS | QUALITY-OF-LIFE | CHEMOTHERAPY | Prospective Studies | Humans | Male | Lutetium - administration & dosage | Prostatic Neoplasms, Castration-Resistant - pathology | Heterocyclic Compounds, 1-Ring - administration & dosage | Neoplasm Metastasis | Time Factors | Kallikreins - blood | Lutetium - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Prostatic Neoplasms, Castration-Resistant - radiotherapy | Dipeptides - adverse effects | Radioisotopes - adverse effects | Victoria | Treatment Outcome | Disease Progression | Prostate-Specific Antigen - blood | Radiopharmaceuticals - administration & dosage | Dipeptides - administration & dosage | Heterocyclic Compounds, 1-Ring - adverse effects | Quality of Life | Radioisotopes - administration & dosage | Aged | Radiopharmaceuticals - adverse effects | Prostatic Neoplasms, Castration-Resistant - diagnostic imaging | Health Status | Clinical trials | Care and treatment | Metastasis | Prostate cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Randomized, Double-Blind, phase 3 trial of triple therapy with dapagliflozin Add-on to saxagliptin plus metformin in type 2 diabetes
by Mathieu, Chantal and Ranetti, Aurelian Emil and Li, Danshi and Ekholm, Ella and Cook, William and Hirshberg, Boaz and Chen, Hungta and Hansen, Lars and Iqbal, Nayyar
Diabetes Care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin | Prescription drugs | Diabetes | Comparative analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy
by Baum, Richard P and Kulkarni, Harshad R and Schuchardt, Christiane and Singh, Aviral and Wirtz, Martina and Wiessalla, Stefan and Schottelius, Margret and Mueller, Dirk and Klette, Ingo and Wester, Hans-Jürgen
Journal of Nuclear Medicine, ISSN 0161-5505, 07/2016, Volume 57, Issue 7, pp. 1006 - 1013
The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand... 
Theranostics | PSMA | Radioligand therapy | Antigens, Surface - therapeutic use | Humans | Male | Positron-Emission Tomography | Antigens, Surface - adverse effects | Patient Selection | Neoplasm Metastasis | Organometallic Compounds - therapeutic use | Pain - etiology | Radiometry | Leukocyte Count | Glutamate Carboxypeptidase II - adverse effects | Glutamate Carboxypeptidase II - therapeutic use | Dipeptides - therapeutic use | Prostatic Neoplasms, Castration-Resistant - radiotherapy | Treatment Outcome | Pain - radiotherapy | Prostate-Specific Antigen - blood | Disease-Free Survival | Heterocyclic Compounds, 1-Ring - therapeutic use | Aged | Radiopharmaceuticals - adverse effects | Prostatic Neoplasms, Castration-Resistant - diagnostic imaging | Erythrocyte Count | Radiopharmaceuticals - therapeutic use | Cohort Studies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
by Scheen, André J and Charpentier, Guillaume and Östgren, Carl Johan and Hellqvist, Åsa and Gause-Nilsson, Ingrid and Linköpings universitet and Primärvården i Finspång and Institutionen för medicin och hälsa and Allmänmedicin and Östergötlands Läns Landsting and Närsjukvården i Finspång and Hälsouniversitetet
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 2010, Volume 26, Issue 7, pp. 540 - 549
Background Dipeptidyl peptidase-4 inhibitors improve glycaemic control in patients with type 2 diabetes mellitus when used as monotherapy or in combination... 
Sitagliptin | Metformin | Type 2 diabetes mellitus | Combination therapy | DPP-4 inhibitor | Saxagliptin | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | MONOTHERAPY | MANAGEMENT | saxagliptin | metformin | RANDOMIZED CONTROLLED-TRIAL | sitagliptin | PIOGLITAZONE | IMPROVES GLYCEMIC CONTROL | VILDAGLIPTIN | ENDOCRINOLOGY & METABOLISM | type 2 diabetes mellitus | combination therapy | TRIPLE THERAPY | Glycated Hemoglobin A - analysis | Triazoles - adverse effects | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Pyrazines - therapeutic use | Metformin - adverse effects | Adamantane - therapeutic use | Female | Sitagliptin Phosphate | Drug Therapy, Combination | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | MEDICINE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
by Ralph A. DeFronzo and Miguel N. Hissa and Alan J. Garber and Jorge Luiz Gross and Raina Yuyan Duan and Shoba Ravichandran and Roland S. Chen and for the Saxagliptin 014 Study Group and Saxagliptin 014 Study Grp and Saxagliptin 014 Study Group and for the Saxagliptin 014 Study Group
Diabetes Care, ISSN 0149-5992, 09/2009, Volume 32, Issue 9, pp. 1649 - 1655
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone Ralph A.... 
ORAL GLUCOSE-TOLERANCE | POTENT | MONOTHERAPY | GLUCAGON-LIKE PEPTIDE-1 | GLYCEMIC DURABILITY | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | INHIBITOR | Metformin - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Placebos | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Dipeptides - pharmacology | Metformin - pharmacology | Treatment Outcome | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Dipeptides - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Medicine, Experimental | Glucose | Pharmaceutical industry | Dextrose | Diabetes therapy | Heart failure | Physical examinations | Drug abuse | Substance abuse treatment | Research methodology | Patient care planning | Diabetes | Safety | Drug therapy | Hypoglycemia | Apoptosis | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial
by Scirica, Benjamin M and Scirica, Benjamin M and Braunwald, Eugene and Raz, Itamar and Cavender, Matthew A and Morrow, David A and Jarolim, Petr and Udell, Jacob A and Mosenzon, Ofri and Im, Kyungah and Umez-Eronini, Amarachi A and Pollack, Pia S and Hirshberg, Boaz and Frederich, Robert and Lewis, Basil S and McGuire, Darren K and Davidson, Jaime and Steg, Ph. Gabriel and Bhatt, Deepak L and SAVOR-TIMI 53 Steering Comm and SAVOR-TIMI 53 Steering Committee and Investigators
Circulation, ISSN 0009-7322, 2014, Volume 130, Issue 18, pp. 1579 - 1588
Background-Diabetes mellitus and heart failure frequently coexist. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart... 
heart failure | saxagliptin | diabetes mellitus | METFORMIN | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | CARDIOVASCULAR OUTCOMES | DEATH | ACUTE CORONARY SYNDROME | CLINICAL-TRIALS | VASCULAR OUTCOMES | PERIPHERAL VASCULAR DISEASE | BLOOD-GLUCOSE CONTROL | TYPE-2 | Multivariate Analysis | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Middle Aged | Male | C-Reactive Protein - metabolism | Troponin T - blood | Peptide Fragments - blood | Female | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - complications | Natriuretic Peptide, Brain - blood | Adamantane - adverse effects | Adamantane - analogs & derivatives | Heart Failure - complications | Risk Assessment | Dipeptides - adverse effects | Heart Failure - metabolism | Hospitalization | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Dipeptides - administration & dosage | Aged | Diabetes Mellitus, Type 2 - drug therapy | Heart Failure - chemically induced | Heart failure | Care and treatment | Usage | Hospital care | Analysis | Diabetes | Diagnosis | Risk factors | Saxagliptin | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
by Barnett, Anthony H and Charbonnel, Bernard and Donovan, Mark and Fleming, Douglas and
Current Medical Research & Opinion, ISSN 0300-7995, 04/2012, Volume 28, Issue 4, pp. 513 - 523
Abstract Objective: To evaluate efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes (T2D) with inadequate glycemic control on... 
Dipeptidyl peptidase-4 inhibitor - DPP-4 - Hypoglycemia - Insulin - Saxagliptin - Type 2 diabetes | Dipeptidyl peptidase-4 inhibitor DPP-4 Hypoglycemia Insulin Saxagliptin Type 2 diabetes | Type 2 diabetes | MEDICINE, RESEARCH & EXPERIMENTAL | MANAGEMENT | EFFICACY | SAFETY | DPP-4 | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | Hypoglycemia | COMBINATION | Insulin | Dipeptidyl peptidase-4 inhibitor | MEDICINE, GENERAL & INTERNAL | PIOGLITAZONE | IMPROVES GLYCEMIC CONTROL | BASAL INSULIN | Saxagliptin | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptides - adverse effects | Humans | Middle Aged | Insulin - administration & dosage | Male | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Metformin - adverse effects | Dipeptides - administration & dosage | Drug Therapy, Combination - methods | Hypoglycemic Agents - administration & dosage | Adolescent | Adult | Female | Aged | Metformin - administration & dosage | Adamantane - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights